博凡格鲁肽(GZR18)注射液

Search documents
甘李药业:GZR102注射液II期临床试验完成首例受试者给药
Zhong Zheng Wang· 2025-08-08 10:56
Group 1 - The core point of the news is that Ganli Pharmaceutical has initiated Phase II clinical trials for its self-developed GZR102 injection, marking a significant advancement in the development of innovative drugs for diabetes treatment [1][2]. - GZR102 is a fixed-dose combination of GZR4 (a long-acting insulin) and GZR18 (a GLP-1 receptor agonist), designed for weekly subcutaneous injection, which aims to enhance glycemic control while minimizing adverse effects such as hypoglycemia and weight gain [1][2]. - The Phase II clinical study will involve 90 participants with poorly controlled type 2 diabetes, comparing the efficacy and safety of GZR102 with GZR18 over a 24-week period [2]. Group 2 - GZR102 is the first domestic fixed-dose combination of basal insulin and GLP-1RA to enter clinical trials, potentially filling a global market gap and establishing China's leadership in diabetes treatment [2]. - The individual components of GZR102, GZR4 and GZR18, have already shown promising results in Phase II trials, demonstrating good safety and efficacy profiles [2]. - Ganli Pharmaceutical has maintained high levels of R&D investment, developing a portfolio of innovative drugs, including the first domestic ultra-long-acting insulin and a pre-mixed insulin combination, positioning itself as a leader in the endocrine and metabolic treatment field [3].